Using Dapagliflozin to Treat Anemia in Patients with Chronic Kidney Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of dapagliflozin, a medication typically used for type 2 diabetes, on anemia in adults with chronic kidney disease (CKD) stages III and IV. The study aims to determine if dapagliflozin can elevate hemoglobin levels in patients who are already receiving erythropoiesis-stimulating agents. By analyzing the outcomes of these patients, the trial seeks to explore the potential benefits of dapagliflozin beyond its primary use. The approach involves monitoring hemoglobin and hematocrit levels in participants over the course of the trial.

Why it matters

Who can join: the full rules

Inclusion criteria

1. Adults aged ≥ 18 years with CKD stage III or IV.
2. Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL
3. Patients are receiving erythropoiesis-stimulating agent therapy.

Exclusion criteria

1. Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.
2. Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma.
3. Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial.
4. Patients with current malignancies or a history of malignancy within the past 2 years.
5. Diagnosed with pure red cell aplasia.
6. Patients with severe gastrointestinal bleeding.
7. Pregnant or lactating females.

Where it's running

• Urology and Nephrology Center
  Al Mansurah, Egypt Recruiting

Study contacts

• Principal investigator: Noha O. Mansour, Ph.D. — Mansoura University
• Study coordinator: Basma M. Sayed Ahmed, M.Sc.
• Email: basma_mohamed@mans.edu.eg
• Phone: +201207753307

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarker-guided treatment strategy for chronic kidney disease

  This trial will test whether using urine biomarkers to guide adding dapagliflozin, finerenone, and/or semaglutide can better reduce albuminuria and protect kidneys in adults with CKD.

  Recruiting Phase 4 Steno Diabetes Center Copenhagen · Herlev and 3 other locations · NCT07239570

• Algae supplements for heart risk markers and gut health

  This trial will test whether daily supplements of spirulina or Gelidium corneum change gut microbes and improve heart‑disease risk markers in adults over 50 with cardiovascular disease, diabetes, or related conditions.

  Recruiting Universidade do Porto · Porto · NCT07173062

• Validating lab assays, IV catheter techniques, and devices for endocrine, cardiometabolic, and musculoskeletal conditions

  This project will test whether laboratory assays, IV catheter methods, and equipment give consistent, reliable results in adults with or without obesity-related, metabolic, or musculoskeletal conditions.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07083557

• Heart, kidney, and metabolic health in Shanghai community residents

  This follow-up will track people from the STONE cohort to see if changes in metabolic risk factors over time relate to heart and kidney outcomes.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07043166

• Safety, tolerability, and how the body handles SK-08 in healthy adults

  This will test whether SK-08 is safe, well tolerated, and how the body processes it in healthy adults aged 18–45.

  Recruiting Phase 1 Consun Pharmaceutical Group · Hangzhou, Zhejiang · NCT07021157

• How common high potassium is and what increases the risk in non-dialysis CKD patients in the community

  This project will test how common high potassium is and try to find which health and lifestyle factors raise the risk in adults with chronic kidney disease who are not on dialysis.

  Recruiting Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, Shanghai Municipality · NCT06940414

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.